Carrier-based strategies for targeting protein and peptide drugs to the lungs.
With greater interest in delivery of protein and peptide-based drugs to the lungs for topical and systemic activity, a range of new devices and formulations are being investigated. While a great deal of recent research has focused on the development of novel devices, attention must now be paid to the formulation of these macromolecular drugs. The emphasis in this review will be on targeting of protein/peptide drugs by inhalation using carriers and ligands.
Cryan
Sally-Ann
SA
School of Pharmacy, Royal College of Surgeons in Ireland, Dublin 2, Ireland. scryan@rcsi.ie
D000280:Administration, Inhalation; D000336:Aerosols; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002451:Cell Compartmentation; D004337:Drug Carriers / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D004339:Drug Compounding; D016503:Drug Delivery Systems / Q000379:methods*; D004342:Drug Hypersensitivity / Q000209:etiology; D004867:Equipment Design; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage / Q000009:adverse effects; D008168:Lung / Q000187:drug effects* / Q000378:metabolism; D008171:Lung Diseases / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D016676:Macrophages, Alveolar / Q000502:physiology; D009330:Nebulizers and Vaporizers; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use; D014677:Pharmaceutical Vehicles / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011208:Powders; D011506:Proteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use; D012120:Respiration Disorders / Q000188:drug therapy; D019141:Respiratory System Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use
D000336:Aerosols; D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D010455:Peptides; D014677:Pharmaceutical Vehicles; D011208:Powders; D011506:Proteins; D019141:Respiratory System Agents; D011092:Polyethylene Glycols